Baxter International Inc. is facing significant safety concerns related to its Novum LVP device, which controls the delivery of intravenous fluids to patients. Reports surfaced in April 2025 of inaccurate infusion rates, prompting at least one hospital system to remove the devices from service. Despite these concerns, Baxter continued promoting the product and initially reported only one serious injury. However, by July 2025, Baxter disclosed that it had received 79 serious injury reports and two patient death reports linked to the Novum LVP. The company issued two warning letters to customers about risks of both underinfusion and overinfusion, but did not instruct hospitals to withdraw the devices from use, instead providing correction steps while allowing continued usage.